Citadel Advisors
ABOS icon

Citadel Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Citadel Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136K Buy
+51,049
New +$126K ﹤0.01% 12428
2026
Q1 		– Sell
-345,283
Closed -$881K – 12862
2025
Q4 		$729K Sell
345,283
-148,825
-30% -$295K ﹤0.01% 8122
2025
Q3 		$845K Buy
+494,108
New +$684K ﹤0.01% 7907
2025
Q1 		– Sell
-9,597
Closed -$13.7K – 14363
2024
Q4 		$16.5K Sell
9,597
-7,315
-43% -$17.6K ﹤0.01% 13299
2024
Q3 		$41.9K Sell
16,912
-66,100
-80% -$179K ﹤0.01% 12098
2024
Q2 		$201K Buy
83,012
+59,661
+255% +$190K ﹤0.01% 9934
2024
Q1 		$94.6K Sell
23,351
-107,765
-82% -$406K ﹤0.01% 11438
2023
Q4 		$503K Buy
131,116
+130,884
+56,416% +$389K ﹤0.01% 8094
2023
Q3 		$963 Sell
232
-47,162
-100% -$291K ﹤0.01% 13945
2023
Q2 		$228K Buy
47,394
+33,313
+237% +$159K ﹤0.01% 9592
2023
Q1 		$57.2K Buy
+14,081
New +$73.5K ﹤0.01% 11991
2022
Q3 		– Sell
-53,749
Closed -$308K – 12480
2022
Q2 		$253K Sell
53,749
-99,498
-65% -$374K ﹤0.01% 10188
2022
Q1 		$599K Buy
153,247
+78,724
+106% +$428K ﹤0.01% 8959
2021
Q4 		$504K Buy
74,523
+35,177
+89% +$387K ﹤0.01% 9681
2021
Q3 		$585K Buy
+39,346
New +$655K ﹤0.01% 9481

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Citadel Advisors's ABOS Position: Q2 2026 in Review

Citadel Advisors opened a new position in Acumen Pharmaceuticals (ABOS) in Q2 2026: 51,049 shares worth $136K. The stake represents ﹤0.01% of the portfolio and ranks #12428 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ABOS as recently as Q4 2025.

Citadel Advisors first reported a position in ABOS in Q3 2021 and has held it in 15 quarters since. The position peaked at $845K in Q3 2025. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Citadel Advisors held 51,049 shares of Acumen Pharmaceuticals worth $136K as of Q2 2026.
  • Acumen Pharmaceuticals was a new Citadel Advisors position in Q2 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12428 holding.
  • Citadel Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
  • Citadel Advisors's Acumen Pharmaceuticals position peaked at $845K in Q3 2025.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.